WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.43 CNY | +3.79% |
|
-1.80% | -37.88% |
| Sales 2022 | 689M 95.06M | Sales 2023 | 602M 83.14M | Capitalization | 4.73B 652M |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.93M | Net income 2023 | -121M -16.7M | EV / Sales 2022 | 4.89 x |
| Net cash position 2022 | 954M 132M | Net cash position 2023 | 1.02B 141M | EV / Sales 2023 | 6.15 x |
| P/E ratio 2022 |
-322
x | P/E ratio 2023 |
-38.8
x | Employees | 1,346 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.31% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.79% | ||
| 1 week | -1.80% | ||
| Current month | -13.26% | ||
| 1 month | -16.31% | ||
| 3 months | -22.12% | ||
| 6 months | -45.09% | ||
| Current year | -37.88% |
1 week
20.48
22.80
1 month
20.1927.36
Current year
18.8036.00
1 year
18.8051.64
3 years
18.8075.00
5 years
18.8085.00
10 years
18.8085.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ya Chen
CEO | Chief Executive Officer | 52 | 04-11-16 |
Huang Chen
CHM | Chairman | 49 | 99-12-31 |
Han Zhen Xia
DFI | Director of Finance/CFO | 61 | 99-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Han Zhen Xia
DFI | Director of Finance/CFO | 61 | 99-12-31 |
Sheng Qiang Li
PRN | Corporate Officer/Principal | 48 | 99-12-31 |
Ya Chen
CEO | Chief Executive Officer | 52 | 04-11-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 22.43 | +3.79% | 1 282 127 |
| 24-04-22 | 21.61 | -0.73% | 1,521,000 |
| 24-04-19 | 21.77 | -1.49% | 921,300 |
| 24-04-18 | 22.1 | -0.23% | 1,076,000 |
| 24-04-17 | 22.15 | +9.22% | 1,918,800 |
End-of-day quote Shenzhen S.E., April 22, 2024
More quotes
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.88% | 390M | |
| +27.74% | 659B | |
| +27.68% | 557B | |
| -4.44% | 359B | |
| +16.35% | 322B | |
| +8.93% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.86% | 149B |
- Stock Market
- Equities
- 300683 Stock
